In a report released today, Tanya Hansalik from UBS maintained a Hold rating on Bachem Holding AG (0QND – Research Report), with a price target of CHF76.00. The company’s shares closed last Friday at CHF67.50.
According to TipRanks, Hansalik is ranked #5056 out of 9178 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Bachem Holding AG with a CHF77.50 average price target.
0QND market cap is currently CHF5.06B and has a P/E ratio of 44.56.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Bachem Holding AG (0QND) Company Description:
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients, as well as on the development of biochemical products for research purposes. The group markets its product under the Bachem and Clinalfa brands. The business of the firm can be seen booming across the market of Switzerland, USA, Austria, Great Britain, Germany and internationally and it generates revenue through the sale of the product.
